Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 8/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
| ▸ | LAP3 | P28838 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ACP3 | P15309 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL858403 | 0.87 | BTN3A1 (0.40) | BTN3A1SRCANPEPLAP3ELANE | |
| SCHEMBL877722 | 0.87 | TDP1 (0.41) | BTN3A1SRCALDH1A1ANPEPLAP3 | |
| SCHEMBL6708631 | 0.86 | LMNA (0.42) | ALDH1A1TDP1KDM4E | |
| SCHEMBL643837 | 0.84 | BTN3A1 (0.40) | BTN3A1SRCANPEPLAP3ELANE | |
| SCHEMBL5996997 | 0.84 | BTN3A1 (0.40) | BTN3A1SRCANPEPLAP3ELANE | |
| SCHEMBL30662658 | 0.84 | KDM4E (0.42) | BTN3A1SRCALDH1A1ANPEPLAP3 | |
| SCHEMBL19668167 | 0.84 | POLB (0.40) | BTN3A1SRCALDH1A1ANPEPLAP3 | |
| SCHEMBL7807907 | 0.83 | KMT2A (0.40) | BTN3A1ALDH1A1HTTKDM4EL3MBTL1 | |
| SCHEMBL29779150 | 0.83 | ELANE (0.49) | BTN3A1ALDH1A1ANPEPLAP3ELANE | |
| SCHEMBL27710787 | 0.83 | ELANE (0.49) | BTN3A1ALDH1A1ANPEPLAP3ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012040126-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| EP-1594976-A4 | ARYL PHOSPHATE DERIVATIVES OF d4T HAVING ACTIVITY AGAINST RESISTANT HIV STRAINS | PARKER HUGHES INST (US) | 2007-11-07 | — | — | EP | disclosed |
| US-20070015733-A1 | Aryl Phosphate Derivatives of d4T having Activity Against Resistant HIV Strains | PARKER HUGHES INSTITUTE (US) | 2007-01-18 | — | — | US | disclosed |
| US-20060293285-A1 | Aryl Phosphate Derivatives of d4T | PARKER HUGHES INSTITUTE (US) | 2006-12-28 | — | — | US | disclosed |
| US-7144874-B2 | Aryl phosphate derivatives of d4T having activity against resistant HIV strains | PARKER HUGHES INSTITUTE (US) | 2006-12-05 | — | — | US | disclosed |
| US-7071176-B2 | Aryl phosphate derivatives of AZT having anti-HIV activity | PARKER HUGHES INSTITUTE (US) | 2006-07-04 | — | — | US | disclosed |
| US-20050277620-A1 | Aryl phosphate derivatives of d4T | PARKER HUGHES INSTITUTE (US) | 2005-12-15 | — | — | US | disclosed |
| EP-1594976-A2 | ARYL PHOSPHATE DERIVATIVES OF d4T HAVING ACTIVITY AGAINST RESISTANT HIV STRAINS | Parker Hughes Institute (US) | 2005-11-16 | — | — | EP | disclosed |
| EP-1334108-B1 | ARYL PHOSPHATE DERIVATIVES OF d4T | PARKER HUGHES INST (US) | 2005-06-15 | — | — | EP | disclosed |
| EP-1090018-B1 | ARYL PHOSPHATE DERIVATIVES OF d4T HAVING ANTI-HIV ACTIVITY | PARKER HUGHES INST (US) | 2004-09-29 | — | — | EP | disclosed |
| US-6537975-B1 | Aryl phosphate derivatives of d4T with para-bromo substitution on the aryl group show markedly increased potency as anti-HIV agents without undesirable levels of cytotoxic activity. In particular, these derivatives are potent | PARKER HUGHES INSTITUTE | 2003-03-25 | — | — | US | disclosed |
| US-6528495-B1 | Para-bromo substitution on the aryl group shows markedly increased potency without undesirable levels of cytotoxic activity; inhibitors of HIV reverse transcriptase; phosphorus of the aryl phosphate is substituted with an amino acid | PARKER HUGHES INSTITUTE | 2003-03-04 | — | — | US | disclosed |
| US-6503890-B1 | Reverse transcriptase inhibitors | PARKER HUGHES INSTITUTE | 2003-01-07 | — | — | US | disclosed |
| WO-2002038576-A1 | ARYL PHOSPHATE DERIVATIVES OF d4T | PARKER HUGHES INSTITUTE (US) | 2002-05-16 | — | — | WO | disclosed |
| US-6350736-B1 | phenyl methoxyalaninyl phosphate derivatives of 2',3'-didehydro-2',3'-dideoxythymidine with an electron-withdrawing moiety, such as p-bromo, for enhanced hydrolysis, have increased potency without high cytotoxic activity; inhibitors of HIV reverse transcriptase; thymidine-kinase (TK)-deficient cells | PARKER HUGHES INSTITUTE | 2002-02-26 | — | — | US | disclosed |
| EP-1090018-A1 | ARYL PHOSPHATE DERIVATIVES OF d4T HAVING ANTI-HIV ACTIVITY | Parker Hughes Institute (US) | 2001-04-11 | — | — | EP | disclosed |
| EP-1068215-A1 | AZT DERIVATIVES EXHIBITING SPERMICIDAL AND ANTI-VIRAL ACTIVITY | Parker Hughes Institute (US) | 2001-01-17 | — | — | EP | disclosed |
| US-6030957-A | INHIBITING HIV(HUMAN IMMUNODEFICIENCY VIRUS) REVERSE TRANSCIPTASE IN CELLS INFECTED WITH HIV BY ADMINISTERING TO INFECTED CELLS ARYLPHOSPHATE DERIVATIVE OF 2',3'-DIDEHYDRO-2',3'-DIDEOXYTHYMIDINE | WAYNE HUGHES INSTITUTE (US) | 2000-02-29 | — | — | US | disclosed |
| WO-2000000501-A1 | ARYL PHOSPHATE DERIVATIVES OF d4T HAVING ANTI-HIV ACTIVITY | PARKER HUGHES INSTITUTE (US) | 2000-01-06 | — | — | WO | disclosed |
| WO-1999048902-A1 | AZT DERIVATIVES EXHIBITING SPERMICIDAL AND ANTI-VIRAL ACTIVITY | PARKER HUGHES INSTITUTE (US) | 1999-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015733-A1 | Aryl Phosphate Derivatives of d4T having Activity Against Resistant HIV Strains | TYMP, PNP, APRT | BTN3A1 3440/4885SRC 1564/4885ALDH1A1 1280/4885 |
| US-20050277620-A1 | Aryl phosphate derivatives of d4T | PNP, MTAP, TYMP | BTN3A1 4432/4885SRC 1803/4885ALDH1A1 2247/4885 |
| US-20060293285-A1 | Aryl Phosphate Derivatives of d4T | PNP, TYMP, APRT | BTN3A1 2932/4885SRC 1684/4885ALDH1A1 1008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.